| Autor: |
Anderson Anuforo, Michael Sandhu, Jianghong Yu, Andras Perl |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Clinical Immunology Communications, Vol 2, Iss , Pp 54-56 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2772-6134 |
| DOI: |
10.1016/j.clicom.2022.03.002 |
| Popis: |
The 2019 Coronavirus disease (COVID-19) vaccine is a major weapon in the fight against the severe acute respiratory syndrome brought about by coronavirus 2 (SARS-CoV-2). The vaccine significantly reduces the risk and severity of infection by SARS-CoV-2. Patients with systemic lupus erythematosus (SLE) need protection from vaccine-preventable diseases including COVID-19. SLE patients have higher rates of severe infections due to immunosuppressive therapies and multiple immunologic defects – both of which are capable of blunting the immune responses after vaccination. In the management of COVID-19, recommendations have been developed to guide adjustments and/or continuation of immunosuppressive therapies for an effective immune response following vaccination with mRNA-based or viral vector-delivered vaccines. Monoclonal antibodies have also become available since December 2021. Here we present three cases of SLE patients who contracted COVID-19 after vaccination. One was managed in ambulatory settings and two required inpatient hospital admission. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
